KR20190041032A - 재조합 vwf의 투여에 의한 응고 질환의 치료 - Google Patents

재조합 vwf의 투여에 의한 응고 질환의 치료 Download PDF

Info

Publication number
KR20190041032A
KR20190041032A KR1020197010327A KR20197010327A KR20190041032A KR 20190041032 A KR20190041032 A KR 20190041032A KR 1020197010327 A KR1020197010327 A KR 1020197010327A KR 20197010327 A KR20197010327 A KR 20197010327A KR 20190041032 A KR20190041032 A KR 20190041032A
Authority
KR
South Korea
Prior art keywords
rvwf
composition
fviii
vwf
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197010327A
Other languages
English (en)
Korean (ko)
Inventor
프리드리히 샤이플링거
페터 투레첵
브루스 에웬스타인
윙 옌 웡
토비아스 엠 주이터
Original Assignee
박스알타 인코퍼레이티드
박스앨타 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 박스알타 인코퍼레이티드, 박스앨타 게엠베하 filed Critical 박스알타 인코퍼레이티드
Priority to KR1020207020667A priority Critical patent/KR102319868B1/ko
Publication of KR20190041032A publication Critical patent/KR20190041032A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
KR1020197010327A 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료 Ceased KR20190041032A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207020667A KR102319868B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161495884P 2011-06-10 2011-06-10
US61/495,884 2011-06-10
US201161511901P 2011-07-26 2011-07-26
US61/511,901 2011-07-26
US201161523790P 2011-08-15 2011-08-15
US61/523,790 2011-08-15
PCT/US2012/041957 WO2012171031A1 (en) 2011-06-10 2012-06-11 Treatment of coagulation disease by administration of recombinant vwf

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020147000709A Division KR101969515B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207020667A Division KR102319868B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료

Publications (1)

Publication Number Publication Date
KR20190041032A true KR20190041032A (ko) 2019-04-19

Family

ID=46321496

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197010327A Ceased KR20190041032A (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료
KR1020147000709A Active KR101969515B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료
KR1020207020667A Active KR102319868B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020147000709A Active KR101969515B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료
KR1020207020667A Active KR102319868B1 (ko) 2011-06-10 2012-06-11 재조합 vwf의 투여에 의한 응고 질환의 치료

Country Status (24)

Country Link
US (2) US9272021B2 (enExample)
EP (3) EP3858375B1 (enExample)
JP (3) JP6347468B2 (enExample)
KR (3) KR20190041032A (enExample)
CN (3) CN108210889A (enExample)
AR (1) AR086904A1 (enExample)
AU (5) AU2012267458A1 (enExample)
BR (1) BR112013031795A2 (enExample)
CA (1) CA2838845C (enExample)
DK (3) DK3412305T3 (enExample)
ES (3) ES2860450T3 (enExample)
FI (1) FI3858375T3 (enExample)
HK (1) HK1257436A1 (enExample)
HR (1) HRP20180962T1 (enExample)
HU (1) HUE039317T2 (enExample)
LT (1) LT2717905T (enExample)
MX (2) MX350582B (enExample)
PL (3) PL3858375T3 (enExample)
PT (3) PT2717905T (enExample)
RU (2) RU2680402C2 (enExample)
SG (2) SG10201604684WA (enExample)
SI (1) SI2717905T1 (enExample)
TR (1) TR201808823T4 (enExample)
WO (1) WO2012171031A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病
CN102776260B (zh) * 2012-07-26 2015-04-29 上海泰龙生物医药科技有限公司 一种高效表达重组人凝血八因子的方法
DK2796145T3 (da) 2013-04-22 2018-01-29 Csl Ltd Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro
NL2013007B1 (en) 2014-06-16 2016-07-05 Ablynx Nv Methods of treating TTP with immunoglobulin single variable domains and uses thereof.
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
SG11201808475XA (en) 2016-04-15 2018-10-30 Baxalta Inc Method and apparatus for providing a pharmacokinetic drug dosing regiment
US10896749B2 (en) 2017-01-27 2021-01-19 Shire Human Genetic Therapies, Inc. Drug monitoring tool
AU2018298232B2 (en) * 2017-07-07 2025-04-03 Takeda Pharmaceutical Company Limited Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant VWF
US10632176B2 (en) 2017-07-07 2020-04-28 Baxalta Incorporated Treatment of gastrointestinal bleeding in patients with severe von Willebrand disease by administration of recombinant VWF
MY204220A (en) 2018-02-06 2024-08-16 Ablynx Nv Methods of treating initial episode of ttp with immunoglobulin single variable domains
MX2020009788A (es) * 2018-03-21 2020-12-09 Takeda Pharmaceuticals Co Separación de factor de von willebrand (vwf) y propéptido de factor de von willebrand (vwf) por métodos cromatográficos.
KR20210134642A (ko) * 2019-02-01 2021-11-10 다케다 야쿠힌 고교 가부시키가이샤 재조합 vwf (rvwf)를 이용한 예방 치료 방법
US20220401524A1 (en) * 2019-09-11 2022-12-22 Takeda Pharmaceutical Company Limited Methods of treatment related to complexes of von willebrand factor and complement c1q
AR121268A1 (es) 2020-02-04 2022-05-04 Takeda Pharmaceuticals Co Tratamiento de la menorragia en pacientes con enfermedad de von willebrand grave mediante la administración de vwf recombinante
IL303089A (en) * 2020-11-24 2023-07-01 Band Therapeutics Llc Compositions and methods for treatment of bleeding disorders
WO2024124136A1 (en) * 2022-12-09 2024-06-13 Vega Therapeutics, Inc. Von willebrand disease animal models

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4638028A (en) 1985-04-08 1987-01-20 Goodyear Tire & Rubber Company Rubber polymerases and methods for their production and use
WO1986006096A1 (en) 1985-04-11 1986-10-23 The Children's Medical Center Corporation Von willebrand factor
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
DE4435485C1 (de) * 1994-10-04 1996-03-21 Immuno Ag Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor
AT403764B (de) * 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT406373B (de) * 1997-02-27 2000-04-25 Immuno Ag Verfahren zur reinigung von faktor viii/vwf-komplex mittels kationenaustauscherchromatographie
AT405403B (de) * 1997-02-27 1999-08-25 Immuno Ag Reinigung von von willebrand-faktor durch kationenaustauscherchromatographie
US6531577B1 (en) 1997-12-15 2003-03-11 Hemasure Denmark A/S von Willebrand factor (vWF)-containing preparation, process for preparing vWF-containing preparations, and use of such preparations
US6864403B1 (en) 1998-10-15 2005-03-08 E. I. Du Pont De Nemours And Company Plant protein disulfide isomerases
US20040014657A1 (en) * 2001-11-05 2004-01-22 Jan Ohrstrom Use of blood coagulation factor XIII for treating haemophilia A
WO2005012354A1 (en) * 2003-07-31 2005-02-10 Zlb Behring Gmbh Method for extending the half-life of fviii
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
KR20070092754A (ko) * 2004-12-27 2007-09-13 백스터 인터내셔널 인코포레이티드 중합체 - 폰 빌레브란트 인자 - 접합체
ES2474573T3 (es) 2006-01-04 2014-07-09 Baxter International Inc Medio de cultivo celular sin oligop�ptidos
JP2010529155A (ja) * 2007-06-13 2010-08-26 ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー 出血性疾患の治療及び予防的処置における血管外投与のためのｖｗｆ安定化ｆｖｉｉｉ製剤及びｆｖｉｉｉなしのｖｗｆ製剤の使用
BRPI0820271A2 (pt) 2007-11-09 2015-05-26 Baxter Int Métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii que inibe receptores de depruração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de ...métodos de aumentar a sobrevivência de uma proteína de coagulação pela inibição da interação com um receptor de depuração, de aumentar a sobrevivência de fator viii pela inibição da interação com um receptor de depuração, de preparar uma composição que inibe receptores de depuração de proteína de coagulação, de tratar um indivíduo com uma doença de coagulação sanguínea, e de tratar uma doença que tem por característica uma deficiência de fator viii em um indivíduo, e, proteína de coagulação modificada.
JP2009127455A (ja) 2007-11-20 2009-06-11 Bando Kiko Co Ltd 往復動エンジン
NZ586383A (en) * 2007-12-28 2012-11-30 Baxter Int Recombinant vwf formulations
ES2298096B1 (es) * 2008-01-08 2009-01-01 Grifols, S.A. Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos.
CN103739712B (zh) 2008-06-24 2016-10-05 德国杰特贝林生物制品有限公司 具有延长的体内半衰期的因子viii、冯·维勒布兰德因子或它们的复合物
TWI670072B (zh) * 2008-10-21 2019-09-01 美商巴克斯歐塔公司 凍乾的重組ｖｗｆ調配物
JP2013500743A (ja) * 2009-08-04 2013-01-10 バクスター・インターナショナル・インコーポレイテッド Ｆｖｉｉｉおよびｖｗｆがノックアウトされた遺伝子導入マウス−血友病ａモデル
ES3037386T3 (en) 2010-07-08 2025-10-01 Takeda Pharmaceuticals Co Method of producing recombinant high molecular weight vwf in cell culture
US20120006800A1 (en) 2010-07-09 2012-01-12 Illinois Tool Works Inc. Weld bead feature communication systems and devices
CN108210889A (zh) * 2011-06-10 2018-06-29 百深有限责任公司 通过施用重组vwf治疗凝血疾病

Also Published As

Publication number Publication date
EP3858375A1 (en) 2021-08-04
HRP20180962T1 (hr) 2018-10-19
RU2014100107A (ru) 2015-07-20
DK3858375T3 (da) 2024-04-15
JP2017019788A (ja) 2017-01-26
KR20200091476A (ko) 2020-07-30
ES2976169T3 (es) 2024-07-24
EP3858375B1 (en) 2024-03-20
PL3412305T3 (pl) 2021-05-31
LT2717905T (lt) 2018-10-10
CA2838845C (en) 2019-08-06
PT3412305T (pt) 2021-01-29
RU2017102679A3 (enExample) 2018-12-19
RU2017102679A (ru) 2018-12-19
FI3858375T3 (fi) 2024-04-17
TR201808823T4 (tr) 2018-07-23
SI2717905T1 (sl) 2018-09-28
EP3412305A1 (en) 2018-12-12
HK1257436A1 (zh) 2019-10-18
NZ618790A (en) 2015-07-31
RU2019103386A (ru) 2020-08-07
KR20140039285A (ko) 2014-04-01
HUE039317T2 (hu) 2018-12-28
ES2682249T3 (es) 2018-09-19
AU2012267458A1 (en) 2014-01-09
KR101969515B1 (ko) 2019-04-16
PL3858375T3 (pl) 2024-05-20
MX2013014543A (es) 2014-06-11
EP3412305B1 (en) 2021-01-06
AU2022201518B2 (en) 2025-07-03
AU2017206235B2 (en) 2019-10-17
AU2016202299B2 (en) 2017-07-20
SG10202002591QA (en) 2020-05-28
MX350582B (es) 2017-09-11
US20160184403A1 (en) 2016-06-30
US20120316116A1 (en) 2012-12-13
RU2680402C2 (ru) 2019-02-21
JP6347468B2 (ja) 2018-06-27
CN107412743B (zh) 2021-07-02
ES2860450T3 (es) 2021-10-05
CN108210889A (zh) 2018-06-29
KR102319868B1 (ko) 2021-11-01
MX2020000083A (es) 2020-08-06
PT3858375T (pt) 2024-04-18
JP2019048892A (ja) 2019-03-28
EP2717905A1 (en) 2014-04-16
CN107412743A (zh) 2017-12-01
JP6527114B2 (ja) 2019-06-05
AU2020200026A1 (en) 2020-01-30
PT2717905T (pt) 2018-07-02
JP2014516088A (ja) 2014-07-07
RU2628537C2 (ru) 2017-08-18
DK3412305T3 (da) 2021-03-01
US9272021B2 (en) 2016-03-01
AU2017206235A1 (en) 2017-08-03
RU2019103386A3 (enExample) 2022-01-24
CN103732244A (zh) 2014-04-16
AU2022201518A1 (en) 2022-03-24
BR112013031795A2 (pt) 2016-12-20
AU2016202299A1 (en) 2016-05-05
SG10201604684WA (en) 2016-07-28
AR086904A1 (es) 2014-01-29
WO2012171031A1 (en) 2012-12-13
PL2717905T3 (pl) 2018-10-31
CA2838845A1 (en) 2012-12-13
DK2717905T3 (en) 2018-07-02
EP2717905B1 (en) 2018-05-23

Similar Documents

Publication Publication Date Title
KR101969515B1 (ko) 재조합 vwf의 투여에 의한 응고 질환의 치료
KR20100095441A (ko) 변형된 재조합 인자 ⅷ 및 폰 빌레브란트 인자 및 사용 방법
JP7641327B2 (ja) 組換えｖｗｆの投与による重度のフォンヴィレブランド病を患う患者における消化管出血の治療
JP7326246B2 (ja) 待機手術を受ける、重度のフォンヴィレブランド病を患う患者の、組換えｖｗｆの投与による治療法
CN113645993A (zh) 使用重组VWF(rVWF)进行预防性治疗的方法
HK40056758A (en) Treatment of coagulation disease by administration of recombinant vwf
HK40056758B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40064201A (en) Methods of prophylactic treatment using recombinant vwf (rvwf)
HK40001633A (en) Treatment of coagulation disease by administration of recombinant vwf
JP2023514541A (ja) 組換えｖｗｆの投与による重症のフォンヴィレブランド病患者における過多月経の治療
HK40001633B (en) Treatment of coagulation disease by administration of recombinant vwf
HK40031159A (en) Treatment of patients with severe von willebrand disease undergoing elective surgery by administration of recombinant vwf
HK1196768B (en) Treatment of coagulation disease by administration of recombinant vwf
HK1196768A (en) Treatment of coagulation disease by administration of recombinant vwf

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190410

Application number text: 1020147000709

Filing date: 20140110

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190701

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200205

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20190701

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200205

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20191001

Comment text: Amendment to Specification, etc.

PX0601 Decision of rejection after re-examination

Comment text: Decision to Refuse Application

Patent event code: PX06014S01D

Patent event date: 20200515

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20200423

Comment text: Decision to Refuse Application

Patent event code: PX06011S01I

Patent event date: 20200205

Comment text: Amendment to Specification, etc.

Patent event code: PX06012R01I

Patent event date: 20191001

Comment text: Notification of reason for refusal

Patent event code: PX06013S01I

Patent event date: 20190701

X601 Decision of rejection after re-examination